Browsing Tag
Rusfertide
3 posts
Does Priority Review signal a commercial breakthrough for Protagonist Therapeutics, Inc.?
Takeda and Protagonist secure FDA Priority Review for rusfertide in PV. Explore the strategic, financial, and competitive implications now.
Wall Street reacts as Johnson & Johnson circles Protagonist Therapeutics in a potential multibillion-dollar buyout
Explore how Johnson & Johnson’s bid to acquire Protagonist Therapeutics could reshape its immunology and hematology pipeline—details inside.
How Protagonist Therapeutics is building a multi‑indication macrocyclic peptide portfolio with icotrokinra and beyond
Protagonist Therapeutics is building a multi-indication oral biologics platform with icotrokinra and rusfertide. Learn how its macrocyclic peptides are redefining therapy.